Products
Glibornuride was commercially available in tablet form (Glutril, originally Roche, later MEDA Pharma). It was approved in many countries since 1971. It was discontinued in 2019.
Structure and properties
Glibornuride (C18H26N2O4S, Mr = 366.48 g/mol) is a sulfonylurea.
Effects
Glibornuride (ATC A10BB04) has antihyperglycemic and antidiabetic properties. The effects are due to the promotion of endogenous insulin secretion from pancreatic beta cells. Glibornuride has a long duration of action of about 24 hours.
Indications
For the treatment of type 2 diabetes.
Dosage
According to the professional information. The tablets are taken in the morning and, for higher doses, also in the evening.
Contraindications
- Hypersensitivity
- Type 1 diabetes
- Ketoacidosis
- Diabetic coma and precoma
- Severe renal and hepatic insufficiency
- Severe adrenocortical insufficiency
- Dysfunction of the thyroid gland and anterior pituitary.
- Hyperglycemia triggered by physical stress situation.
- Pregnancy and lactation
Full precautions can be found in the drug label.
Interactions
Numerous agents affect blood glucose and may promote the development of hypoglycemia.
Adverse effects
Possible adverse effects include:
- Hypoglycemia, hyponatremia, hepatic porphyria, porphyria cutanea tarda.
- Dizziness, drowsiness, headache
- Nausea, bloating, diarrhea, constipation.
- Blood count disorders
- Cholestatic jaundice
- Allergic skin reactions
